 Home > Active Ingredient News > Antitumor Therapy > Front Oncol: Fruquintinib + PD-1 inhibitor vs. Regorafenib + PD-1 inhibitor in the treatment of patients with refractory microsatellite stable metastatic colorectal cancer

Front Oncol: Fruquintinib + PD-1 inhibitor vs. Regorafenib + PD-1 inhibitor in the treatment of patients with refractory microsatellite stable metastatic colorectal cancer

 Last Update: 2021-10-10
 Source: Internet
 Author: User

Tags

hijiki seaweed cancer

2 4 hexadiene

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Colorectal cancer ranks third in global incidence and second in mortality
.

For patients with advanced colorectal cancer who have progressed to standard first-line and second-line treatments, third-line treatments include regorafenib, fruquintinib, and TAS-102, but the efficacy is moderate

Colorectal cancer ranks third in global incidence and second in mortality

The study retrospectively collected data from patients with MSS or pMMR mCRC from June 2019 to March 2021
.

The analysis compared the efficacy and safety of FP and RP

The study retrospectively collected data from patients with MSS or pMMR mCRC from June 2019 to March 2021

A total of 51 patients were included in the study, of which 28 were treated with FP regimen and 23 were treated with RP regimen

The ORR of the whole population was 7.

Efficacy evaluation

The median progression-free survival (PFS) of the FP group was 6.
4 months (HR = 0.
445; 95% CI: 5.
527-7.
273), and the RP group was 3.
9 months (HR = 0.
594; 95% CI: 2.
736-5.
064).
The difference It is statistically significant (P = 0.
0209)
.

The median progression-free survival (PFS) of the FP group was 6.

PFS

PFSPFS

Among patients without liver metastasis, the median progression-free survival (PFS) between the FP group and the RP group was significantly different (P<0.
0001), but there was no statistically significant difference in patients with liver metastasis (P>0.
05)
.

For KRAS wild-type patients, the median PFS between the FP group and the RP group was significantly different (P=0.

Among patients without liver metastasis, the median progression-free survival (PFS) between the FP group and the RP group was significantly different (P<0.

Subgroup analysis PFS

The adverse events of 28 patients in the FP group and 23 patients in the RP group were evaluated
.

All patients experienced adverse events

The adverse events of 28 patients in the FP group and 23 patients in the RP group were evaluated

Multivariate analysis showed that the treatment of fruquintinib versus regorafenib was an independent risk factor for PFS (HR = 2.
688; 95%CI: 1.
246 5.
797; P = 0.
012)
.
Multivariate analysis showed that the treatment of fruquintinib versus regorafenib was an independent risk factor for PFS (HR = 2.
688; 95%CI: 1.
246 5.
797; P = 0.
012)
.

Multivariate PFS risk factors

In summary, the study shows that Fruquintinib + PD-1 inhibitor (FP) can improve PFS in patients with refractory microsatellite stable (MSS) metastatic colorectal cancer
.

In summary, the study shows that Fruquintinib + PD-1 inhibitor (FP) can improve PFS in patients with refractory microsatellite stable (MSS) metastatic colorectal cancer
.
The study showed that Fruquintinib + PD-1 inhibitor (FP) can improve PFS in patients with refractory microsatellite stable (MSS) metastatic colorectal cancer
.
The study showed that Fruquintinib + PD-1 inhibitor (FP) can improve PFS in patients with refractory microsatellite stable (MSS) metastatic colorectal cancer
.

Original source:

Sun L, Huang S, Li D, Mao Y, Wang Y and Wu J (2021) Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitors Versus Regorafenib Plus PD-1 Inhibitors in Refractory Microsatellite Stable Metastatic Colorectal Cancer.
Front.
Oncol.
11 :754881.
doi: 10.
3389/fonc.
2021.
754881

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.